Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease.
Viswanath DevanarayanThomas DohertyArnaud CharilPallavi SachdevYuanqing YeLeema Krishna MuraliDaniel A LlanoJin ZhouLarisa ReydermanHarald HampelLynn D KramerShobha DhaddaMichael C IrizarryPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
NCT02956486 (MissionAD1), NCT03036280 (MissionAD2), NCT04468659 (AHEAD3-45), NCT03887455 (ClarityAD) HIGHLIGHTS: Phosphorylated plasma Tau217 ratio (pTau217R) effectively predicts amyloid-PET Centiloid (CL) across a broad spectrum. Integrating pTau217R with Aβ42/Aβ40 extends the CL prediction upper limit to 89.1 CL. Combined model predicts amyloid status with high accuracy, especially in cognitively unimpaired individuals. This model identifies subjects above or below various CL thresholds with high accuracy. pTau217R-based models significantly reduce PET scans by up to 78.6% for screening out individuals with no/low amyloid.
Keyphrases
- computed tomography
- positron emission tomography
- cognitive decline
- pet ct
- white matter
- genome wide
- multiple sclerosis
- pet imaging
- stem cells
- resting state
- magnetic resonance
- mild cognitive impairment
- cell therapy
- dna methylation
- mesenchymal stem cells
- cerebrospinal fluid
- functional connectivity
- brain injury
- bone marrow
- cerebral ischemia
- dual energy